Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial (Q44525441)
Jump to navigation
Jump to search
scientific article published in February 2008
Language | Label | Description | Also known as |
---|---|---|---|
English | Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial |
scientific article published in February 2008 |
Statements
1 reference
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial (English)
1 reference
Alexa B Kimball
1 reference
Kenneth B Gordon
1 reference
Richard G Langley
1 reference
Alan Menter
1 reference
Elliot K Chartash
1 reference
Joaquin Valdes
1 reference
ABT-874 Psoriasis Study Investigators
1 reference
1 February 2008
1 reference
1 reference
144
1 reference
2
1 reference
200-207
1 reference
Identifiers
1 reference
1 reference